Novartis First-Generation Lung Cancer Drug Tweaked To Reduce Potential Side Effects

New Drug Approvals

Structures of anaplastic lymphoma kinase inhibitors
IMPROVING A DRUG
Novartis’ first-generation inhibitor of the enzyme anaplastic lymphoma kinase (TAE684, left) formed potentially harmful protein adducts in the body. To reduce side effects, chemists moved the position of a troublesome nitrogen to make the current version of the drug (LDK378, right).
Credit: J. Med. Chem.
read all at

View original post

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s